Unlock stock picks and a broker-level newsfeed that powers Wall Street.
NYSE - Nasdaq Real Time Price USD

Abbott Laboratories (ABT)

Compare
124.44
-7.19
(-5.46%)
At close: April 4 at 4:00:02 PM EDT
125.00
+0.56
+(0.45%)
After hours: April 4 at 7:59:39 PM EDT
Loading Chart for ABT
  • Previous Close 131.63
  • Open 131.23
  • Bid 123.45 x 800
  • Ask 127.03 x 900
  • Day's Range 124.00 - 132.40
  • 52 Week Range 99.71 - 141.23
  • Volume 10,775,205
  • Avg. Volume 6,983,933
  • Market Cap (intraday) 215.819B
  • Beta (5Y Monthly) 0.80
  • PE Ratio (TTM) 16.29
  • EPS (TTM) 7.64
  • Earnings Date Apr 16, 2025
  • Forward Dividend & Yield 2.36 (1.90%)
  • Ex-Dividend Date Apr 15, 2025
  • 1y Target Est 136.68

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company provides pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

www.abbott.com

114,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: ABT

View More

Performance Overview: ABT

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ABT
10.59%
S&P 500 (^GSPC)
13.73%

1-Year Return

ABT
15.32%
S&P 500 (^GSPC)
1.42%

3-Year Return

ABT
10.92%
S&P 500 (^GSPC)
10.72%

5-Year Return

ABT
71.07%
S&P 500 (^GSPC)
103.89%

Compare To: ABT

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ABT

View More

Valuation Measures

As of 4/4/2025
  • Market Cap

    215.82B

  • Enterprise Value

    222.87B

  • Trailing P/E

    16.29

  • Forward P/E

    24.15

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    5.19

  • Price/Book (mrq)

    4.53

  • Enterprise Value/Revenue

    5.31

  • Enterprise Value/EBITDA

    20.66

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    31.95%

  • Return on Assets (ttm)

    6.06%

  • Return on Equity (ttm)

    30.91%

  • Revenue (ttm)

    41.95B

  • Net Income Avi to Common (ttm)

    13.35B

  • Diluted EPS (ttm)

    7.64

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    7.97B

  • Total Debt/Equity (mrq)

    31.89%

  • Levered Free Cash Flow (ttm)

    5.61B

Research Analysis: ABT

View More

People Also Watch